These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7796105)

  • 1. Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments.
    Schneider JS; DiStefano L
    Brain Res; 1995 Mar; 674(2):260-4. PubMed ID: 7796105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons.
    Rothblat DS; Schneider JS
    Brain Res; 1998 Jan; 779(1-2):226-30. PubMed ID: 9473679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GM1 ganglioside treatment partially reverses the nigrostriatal dopamine defect in the weaver mutant mouse.
    Schneider JS; Smith MG; DiStefano L; Berrian J
    Brain Res; 1994 Feb; 636(2):353-6. PubMed ID: 7912161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.
    Hadjiconstantinou M; Mariani AP; Neff NH
    Brain Res; 1989 Apr; 484(1-2):297-303. PubMed ID: 2565752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GM1 ganglioside restores dopaminergic neurochemical and morphological markers in aged rats.
    Goettl VM; Wemlinger TA; Duchemin AM; Neff NH; Hadjiconstantinou M
    Neuroscience; 1999; 92(3):991-1000. PubMed ID: 10426539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism.
    Schneider JS; Yuwiler A
    Exp Neurol; 1989 Aug; 105(2):177-83. PubMed ID: 2568945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion.
    Chadi G; Møller A; Rosén L; Janson AM; Agnati LA; Goldstein M; Ogren SO; Pettersson RF; Fuxe K
    Exp Brain Res; 1993; 97(1):145-58. PubMed ID: 7907549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GM1 ganglioside enhances Ret signaling in striatum.
    Newburn EN; Duchemin AM; Neff NH; Hadjiconstantinou M
    J Neurochem; 2014 Aug; 130(4):541-54. PubMed ID: 24821093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse.
    Hadjiconstantinou M; Neff NH
    J Neurochem; 1988 Oct; 51(4):1190-6. PubMed ID: 3262149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
    Schneider JS; Kean A; DiStefano L
    J Neurosci Res; 1995 Sep; 42(1):117-23. PubMed ID: 8531220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of GM1 ganglioside treatment on dopamine innervation of the striatum of MPTP-treated mice.
    Rothblat DS; Schneider JS
    Ann N Y Acad Sci; 1998 Jun; 845():274-7. PubMed ID: 9668361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
    Schneider JS
    J Neurosci Res; 1992 Jan; 31(1):112-9. PubMed ID: 1613817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LIGA 20 increases striatal dopamine levels in aged MPTP-treated mice refractory to GM1 ganglioside treatment.
    Schneider JS; DiStefano L
    Neuroreport; 1993 Nov; 5(2):103-4. PubMed ID: 8110995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
    Pope-Coleman A; Tinker JP; Schneider JS
    Synapse; 2000 May; 36(2):120-8. PubMed ID: 10767059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.
    Schneider JS; Pope A; Simpson K; Taggart J; Smith MG; DiStefano L
    Science; 1992 May; 256(5058):843-6. PubMed ID: 1350379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GM1 ganglioside partially rescues cultured dopaminergic neurons from MPP(+)-induced damage: dependence on initial damage and time of treatment.
    Stull ND; Schneider JS; Iacovitti L
    Brain Res; 1994 Mar; 640(1-2):308-15. PubMed ID: 7911728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of the damaged dopamine system to GM1 and semisynthetic gangliosides: effects of dose and extent of lesion.
    Schneider JS; Distefano L
    Neuropharmacology; 1995 May; 34(5):489-93. PubMed ID: 7566482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
    Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
    Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor enhances striatal dopaminergic parameters in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse.
    Hadjiconstantinou M; Fitkin JG; Dalia A; Neff NH
    J Neurochem; 1991 Aug; 57(2):479-82. PubMed ID: 1677029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of age on GM1 ganglioside-induced recovery of concentrations of dopamine in the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
    Schneider JS
    Neuropharmacology; 1992 Feb; 31(2):185-92. PubMed ID: 1553028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.